Literature DB >> 19164153

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Susanne Perkhofer1, Veronika Lechner, Cornelia Lass-Flörl.   

Abstract

We evaluated the MICs of isavuconazole (ISAV) against 96 isolates of Aspergillus species and 36 zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. In addition, the in vitro activity was obtained for hyphal inocula. ISAV exhibited good antifungal activity against the tested isolates with the exception of Aspergillus niger and Mucorales. The in vitro activity of ISAV was comparable to that of voriconazole aside from Mucorales.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164153      PMCID: PMC2663115          DOI: 10.1128/AAC.01530-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Infections due to emerging and uncommon medically important fungal pathogens.

Authors:  T J Walsh; A Groll; J Hiemenz; R Fleming; E Roilides; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

2.  Caspofungin in the treatment of candidosis and aspergillosis.

Authors:  Johan Maertens; Marc Boogaerts
Journal:  Int J Infect Dis       Date:  2003-06       Impact factor: 3.623

3.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

Review 4.  Invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

5.  Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.

Authors:  C Lass-Flörl; M Nagl; C Speth; H Ulmer; M P Dierich; R Würzner
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

7.  Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; A Fothergill; J Peter; M G Rinaldi; T J Walsh
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

8.  A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT.

Authors:  S M Levitz; R D Diamond
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

9.  Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; V Chaturvedi; A Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

View more
  27 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

Authors:  George R Thompson; Nathan P Wiederhold
Journal:  Mycopathologia       Date:  2010-06-05       Impact factor: 2.574

3.  Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.

Authors:  Mariana Castanheira; Shawn A Messer; Paul R Rhomberg; Rachel R Dietrich; Ronald N Jones; Michael A Pfaller
Journal:  Mycopathologia       Date:  2014-06-21       Impact factor: 2.574

Review 4.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

5.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

6.  Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.

Authors:  Susan J Howard; Cornelia Lass-Flörl; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maiken C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

Review 7.  Challenges in the diagnosis and treatment of mucormycosis.

Authors:  A Skiada; C Lass-Floerl; N Klimko; A Ibrahim; E Roilides; G Petrikkos
Journal:  Med Mycol       Date:  2018-04-01       Impact factor: 4.076

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

Authors:  Matthew W McCarthy; Brad Moriyama; Ruta Petraitiene; Thomas J Walsh; Vidmantas Petraitis
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

9.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; C Lass-Flörl; E Martin-Mazuelos; J Meis; T Peláez; M A Pfaller; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.

Authors:  Peter A Warn; Andrew Sharp; Arvind Parmar; Jayesh Majithiya; David W Denning; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.